Fiera Capital Corp Boosts Stock Position in argenex SE $ARGX

Fiera Capital Corp raised its holdings in argenex SE (NASDAQ:ARGX) by 12.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 177,654 shares of the company’s stock after purchasing an additional 19,180 shares during the period. Fiera Capital Corp owned about 0.29% of argenex worth $131,030,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ARGX. GAMMA Investing LLC increased its stake in shares of argenex by 6.8% in the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock worth $185,000 after buying an additional 16 shares during the last quarter. Portside Wealth Group LLC grew its holdings in argenex by 2.8% during the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock worth $430,000 after acquiring an additional 16 shares in the last quarter. Cromwell Holdings LLC increased its position in shares of argenex by 10.0% in the 3rd quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock worth $138,000 after purchasing an additional 17 shares during the last quarter. Main Management ETF Advisors LLC raised its stake in shares of argenex by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock valued at $808,000 after purchasing an additional 24 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of argenex by 1.1% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 2,126 shares of the company’s stock valued at $1,568,000 after purchasing an additional 24 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Price Performance

NASDAQ:ARGX opened at $847.26 on Friday. The firm has a market capitalization of $52.43 billion, a P/E ratio of 36.38, a P/E/G ratio of 0.73 and a beta of 0.37. The business has a 50 day simple moving average of $831.90 and a 200 day simple moving average of $804.81. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ARGX shares. Wells Fargo & Company lifted their price target on argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. DZ Bank upgraded argenex to a “strong-buy” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Finally, Stifel Nicolaus raised their price objective on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $986.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.